Ibrutinib (Imbruvica®). HTA ID: 22054

Assessment Status Full HTA submission received from Applicant
HTA ID 22054
Drug Ibrutinib
Brand Imbruvica®
Indication In combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
Assessment Process
Rapid review commissioned 27/07/2022
Rapid review completed 02/09/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ibrutinib in combination with venetoclax compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/09/2022
Pre-submission consultation with Applicant 14/11/2022
Full submission received from Applicant 14/02/2023